  In Oncology, trials evaluating drug combinations are becoming more common.
While combination therapies bring the potential for greater efficacy, they also
create unique challenges for ensuring drug safety. In Phase-I dose escalation
trials of drug combinations, model-based approaches enable efficient use of
information gathered, but the models need to account for trial complexities:
appropriate modeling of interactions becomes increasingly important with
growing numbers of drugs being tested simultaneously in a given trial. In
principle, we can use data from multiple arms testing varying combinations to
jointly estimate toxicity of the drug combinations. However, such efforts have
highlighted limitations when modelling drug-drug interactions in the Bayesian
Logistic Regression Model (BLRM) framework used to ensure patient safety.
Previous models either do not account for non-monotonicity due to antagonistic
toxicity, or exhibit the fundamental flaw of exponentially overpowering the
contributions of the individual drugs in the dose-response. This specifically
leads to issues when drug combinations exhibit antagonistic toxicity, in which
case the toxicity probability gets vanishingly small as doses get very large.
  We put forward additional constraints inspired by Paracelsus' intuition of
"the dose makes the poison" which avoid this flaw and present an improved
interaction model which is compatible with these constraints. We create
instructive data scenarios that showcase the improved behavior of this more
constrained drug-drug interaction model in terms of preventing further dosing
at overly toxic dose combinations and more sensible dose-finding under
antagonistic drug toxicity. This model is now available in the open-source
OncoBayes2 R package that implements the BLRM framework for an arbitrary number
of drugs and trial arms.
